Financhill
Sell
41

VTAK Quote, Financials, Valuation and Earnings

Last price:
$0.40
Seasonality move :
-35.2%
Day range:
$0.34 - $0.42
52-week range:
$0.30 - $8.40
Dividend yield:
0%
P/E ratio:
0.41x
P/S ratio:
0.96x
P/B ratio:
0.22x
Volume:
61.8K
Avg. volume:
166K
1-year change:
-93.36%
Market cap:
$2.9M
Revenue:
$442K
EPS (TTM):
$0.88

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VTAK
Catheter Precision
$280K -$0.20 118.75% -11.57% --
CATX
Perspective Therapeutics
$277.3K -$0.26 -- -41.72% $15.58
INFU
InfuSystems Holdings
$34.9M $0.06 5.54% -40% $14.13
RVP
Retractable Technologies
-- -- -- -- --
VNRX
VolitionRX
$545.3K -$0.05 123.53% -54.55% $3.37
XTNT
Xtant Medical Holdings
$31.8M -$0.02 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VTAK
Catheter Precision
$0.36 -- $2.9M 0.41x $0.00 0% 0.96x
CATX
Perspective Therapeutics
$2.59 $15.58 $175.1M -- $0.00 0% 13.99x
INFU
InfuSystems Holdings
$5.55 $14.13 $116.6M 55.50x $0.00 0% 0.89x
RVP
Retractable Technologies
$0.75 -- $22.3M -- $0.00 0% 0.58x
VNRX
VolitionRX
$0.58 $3.37 $53.9M -- $0.00 0% 37.56x
XTNT
Xtant Medical Holdings
$0.49 $1.75 $67.7M -- $0.00 0% 0.56x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VTAK
Catheter Precision
12% -2.395 128.21% 0.53x
CATX
Perspective Therapeutics
-- -3.661 -- --
INFU
InfuSystems Holdings
29.32% 2.514 13.28% 1.23x
RVP
Retractable Technologies
1.55% -0.326 11.72% 5.80x
VNRX
VolitionRX
-28.76% -0.785 8.83% 0.19x
XTNT
Xtant Medical Holdings
44.29% 0.232 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$18.2M $2.6M 2.82% 4.33% 7.76% $2.8M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Catheter Precision vs. Competitors

  • Which has Higher Returns VTAK or CATX?

    Perspective Therapeutics has a net margin of -4291.67% compared to Catheter Precision's net margin of --. Catheter Precision's return on equity of -65.84% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About VTAK or CATX?

    Catheter Precision has a consensus price target of --, signalling upside risk potential of 456.33%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 501.43%. Given that Perspective Therapeutics has higher upside potential than Catheter Precision, analysts believe Perspective Therapeutics is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTAK
    Catheter Precision
    0 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is VTAK or CATX More Risky?

    Catheter Precision has a beta of -0.541, which suggesting that the stock is 154.132% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

  • Which is a Better Dividend Stock VTAK or CATX?

    Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTAK or CATX?

    Catheter Precision quarterly revenues are $96K, which are larger than Perspective Therapeutics quarterly revenues of --. Catheter Precision's net income of -$4.1M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Catheter Precision's price-to-earnings ratio is 0.41x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.96x versus 13.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTAK
    Catheter Precision
    0.96x 0.41x $96K -$4.1M
    CATX
    Perspective Therapeutics
    13.99x -- -- -$15.1M
  • Which has Higher Returns VTAK or INFU?

    InfuSystems Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of 2.76%. Catheter Precision's return on equity of -65.84% beat InfuSystems Holdings's return on equity of 4.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
    INFU
    InfuSystems Holdings
    53.82% $0.04 $81.4M
  • What do Analysts Say About VTAK or INFU?

    Catheter Precision has a consensus price target of --, signalling upside risk potential of 456.33%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 154.51%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTAK
    Catheter Precision
    0 0 0
    INFU
    InfuSystems Holdings
    4 0 0
  • Is VTAK or INFU More Risky?

    Catheter Precision has a beta of -0.541, which suggesting that the stock is 154.132% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.755, suggesting its more volatile than the S&P 500 by 75.5%.

  • Which is a Better Dividend Stock VTAK or INFU?

    Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTAK or INFU?

    Catheter Precision quarterly revenues are $96K, which are smaller than InfuSystems Holdings quarterly revenues of $33.8M. Catheter Precision's net income of -$4.1M is lower than InfuSystems Holdings's net income of $933K. Notably, Catheter Precision's price-to-earnings ratio is 0.41x while InfuSystems Holdings's PE ratio is 55.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.96x versus 0.89x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTAK
    Catheter Precision
    0.96x 0.41x $96K -$4.1M
    INFU
    InfuSystems Holdings
    0.89x 55.50x $33.8M $933K
  • Which has Higher Returns VTAK or RVP?

    Retractable Technologies has a net margin of -4291.67% compared to Catheter Precision's net margin of -18.58%. Catheter Precision's return on equity of -65.84% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About VTAK or RVP?

    Catheter Precision has a consensus price target of --, signalling upside risk potential of 456.33%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision has higher upside potential than Retractable Technologies, analysts believe Catheter Precision is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTAK
    Catheter Precision
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is VTAK or RVP More Risky?

    Catheter Precision has a beta of -0.541, which suggesting that the stock is 154.132% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.083, suggesting its more volatile than the S&P 500 by 108.265%.

  • Which is a Better Dividend Stock VTAK or RVP?

    Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios VTAK or RVP?

    Catheter Precision quarterly revenues are $96K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Catheter Precision's net income of -$4.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Catheter Precision's price-to-earnings ratio is 0.41x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.96x versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTAK
    Catheter Precision
    0.96x 0.41x $96K -$4.1M
    RVP
    Retractable Technologies
    0.58x -- $10.3M -$1.9M
  • Which has Higher Returns VTAK or VNRX?

    VolitionRX has a net margin of -4291.67% compared to Catheter Precision's net margin of -1226.82%. Catheter Precision's return on equity of -65.84% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About VTAK or VNRX?

    Catheter Precision has a consensus price target of --, signalling upside risk potential of 456.33%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 479.61%. Given that VolitionRX has higher upside potential than Catheter Precision, analysts believe VolitionRX is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTAK
    Catheter Precision
    0 0 0
    VNRX
    VolitionRX
    2 1 0
  • Is VTAK or VNRX More Risky?

    Catheter Precision has a beta of -0.541, which suggesting that the stock is 154.132% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

  • Which is a Better Dividend Stock VTAK or VNRX?

    Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTAK or VNRX?

    Catheter Precision quarterly revenues are $96K, which are smaller than VolitionRX quarterly revenues of $474.5K. Catheter Precision's net income of -$4.1M is higher than VolitionRX's net income of -$5.8M. Notably, Catheter Precision's price-to-earnings ratio is 0.41x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.96x versus 37.56x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTAK
    Catheter Precision
    0.96x 0.41x $96K -$4.1M
    VNRX
    VolitionRX
    37.56x -- $474.5K -$5.8M
  • Which has Higher Returns VTAK or XTNT?

    Xtant Medical Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of -10.04%. Catheter Precision's return on equity of -65.84% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About VTAK or XTNT?

    Catheter Precision has a consensus price target of --, signalling upside risk potential of 456.33%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 259.34%. Given that Catheter Precision has higher upside potential than Xtant Medical Holdings, analysts believe Catheter Precision is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTAK
    Catheter Precision
    0 0 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is VTAK or XTNT More Risky?

    Catheter Precision has a beta of -0.541, which suggesting that the stock is 154.132% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

  • Which is a Better Dividend Stock VTAK or XTNT?

    Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTAK or XTNT?

    Catheter Precision quarterly revenues are $96K, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Catheter Precision's net income of -$4.1M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Catheter Precision's price-to-earnings ratio is 0.41x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 0.96x versus 0.56x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTAK
    Catheter Precision
    0.96x 0.41x $96K -$4.1M
    XTNT
    Xtant Medical Holdings
    0.56x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

Sell
50
NUTX alert for Mar 15

Nutex Health [NUTX] is up 14.56% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock